Upstream Bio, Inc.

Upstream Bio is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, that develops immunology-focused treatments for inflammatory diseases, particularly severe respiratory disorders. The company's primary therapeutic candidate is verekitug, which targets underlying disease mechanisms in conditions characterized by abnormal immune responses. Verekitug is currently in Phase 2 clinical development for severe asthma and chronic rhinosinusitis with nasal polyps, with an additional Phase 1 trial underway for chronic obstructive pulmonary disease.

As a pre-commercial clinical-stage company, Upstream Bio does not currently generate revenue from product sales. The company operates with a lean organizational structure of 52 full-time employees and is incorporated in Delaware with its operations based in the Boston area. The company was founded in 2021 and is listed on Nasdaq, indicating public capital market access to fund ongoing clinical development and operational activities.